Lpath Inc. closed the second tranche of an April private placement, for a total financing of $16.8 million to push its lead compound, the anti-angiogenic compound Sphingomab, into the clinic.(BioWorld Today)
Lpath Inc. closed the second tranche of an April private placement, for a total financing of $16.8 million to push its lead compound, the anti-angiogenic compound Sphingomab, into the clinic.(BioWorld Today)
While it awaits further Phase II data from its lead E21 Pathway activator in multiple cancer indications, ArQule Inc. padded its bank account with a $54.3 million public offering of 7 million shares priced at $7.75 each.(BioWorld Today)
While it awaits further Phase II data from its lead E21 Pathway activator in multiple cancer indications, ArQule Inc. padded its bank account with a $54.3 million public offering of 7 million shares priced at $7.75 each.(BioWorld Today)
Logical Therapeutics Inc., which develops drugs for diseases associated with or caused by inflammation, raised $30 million in its Series B round to push its early stage pipeline through proof-of-concept trials, starting with a naproxen prodrug aimed at chronic pain.(BioWorld Today)
Logical Therapeutics Inc., which develops drugs for diseases associated with or caused by inflammation, raised $30 million in its Series B round to push its early stage pipeline through proof-of-concept trials, starting with a naproxen prodrug aimed at chronic pain.(BioWorld Today)
